Translating plasma eicosapentaenoic acid (EPA) concentrations into erythrocyte percentages of EPA plus docosahexaenoic acid (DHA) during treatment with icosapent ethyl

The REDUCE-IT study demonstrated that 4 g/day of eicosapentaenoic acid (EPA) ethyl esters (icosapent ethyl, IPE) reduced risk for major cardiovascular events by 25% in statin-treated patients with residual hypertriglyceridemia. How this treatment affected red blood cell (RBC) EPA and docosahexaenoic acid (DHA) levels (i.e., the omega-3 index, O3I) was not reported, but effects on plasma EPA concentrations were.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research